SUBLOCADE

AssetAlso called Buprenorphine, Brixadi, Bupeaze, Buplast

Provides extended-release buprenorphine by subcutaneous injection.

Stage
Approved
Modality
Not known
Target
OPRM1
14
Indications
259
Trials
1
Developer

Approved by the FDA on Nov 30, 2017 (NDA209819). FDA

Indications

14

11 more

In the full profile

  • Target and mechanism3
  • Owner and partners1
  • Trials259
  • Evidence for its targets3
  • Competitors12
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets